Lipocine (LPCN) Competitors $3.27 -0.05 (-1.51%) Closing price 07/11/2025 04:00 PM EasternExtended Trading$3.30 +0.03 (+0.89%) As of 07/11/2025 06:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock LPCN vs. PYXS, BMEA, INCR, ABOS, IMUX, IKNA, MNOV, IZTC, ADAP, and IGMSShould you be buying Lipocine stock or one of its competitors? The main competitors of Lipocine include Pyxis Oncology (PYXS), Biomea Fusion (BMEA), InterCure (INCR), Acumen Pharmaceuticals (ABOS), Immunic (IMUX), Ikena Oncology (IKNA), MediciNova (MNOV), Invizyne Technologies (IZTC), Adaptimmune Therapeutics (ADAP), and IGM Biosciences (IGMS). These companies are all part of the "pharmaceutical products" industry. Lipocine vs. Its Competitors Pyxis Oncology Biomea Fusion InterCure Acumen Pharmaceuticals Immunic Ikena Oncology MediciNova Invizyne Technologies Adaptimmune Therapeutics IGM Biosciences Pyxis Oncology (NASDAQ:PYXS) and Lipocine (NASDAQ:LPCN) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, dividends, institutional ownership, risk, media sentiment, profitability, analyst recommendations and earnings. Does the media refer more to PYXS or LPCN? In the previous week, Pyxis Oncology had 3 more articles in the media than Lipocine. MarketBeat recorded 4 mentions for Pyxis Oncology and 1 mentions for Lipocine. Pyxis Oncology's average media sentiment score of 0.99 beat Lipocine's score of 0.93 indicating that Pyxis Oncology is being referred to more favorably in the media. Company Overall Sentiment Pyxis Oncology Positive Lipocine Positive Which has stronger earnings & valuation, PYXS or LPCN? Lipocine has lower revenue, but higher earnings than Pyxis Oncology. Lipocine is trading at a lower price-to-earnings ratio than Pyxis Oncology, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPyxis Oncology$16.15M4.45-$77.33M-$1.59-0.73Lipocine$11.20M1.56$10K-$1.02-3.21 Do analysts recommend PYXS or LPCN? Pyxis Oncology currently has a consensus target price of $9.00, indicating a potential upside of 675.86%. Lipocine has a consensus target price of $9.00, indicating a potential upside of 175.23%. Given Pyxis Oncology's higher probable upside, equities analysts clearly believe Pyxis Oncology is more favorable than Lipocine.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Pyxis Oncology 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.80Lipocine 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has more volatility and risk, PYXS or LPCN? Pyxis Oncology has a beta of 1.13, suggesting that its share price is 13% more volatile than the S&P 500. Comparatively, Lipocine has a beta of 1.3, suggesting that its share price is 30% more volatile than the S&P 500. Is PYXS or LPCN more profitable? Lipocine's return on equity of -26.68% beat Pyxis Oncology's return on equity.Company Net Margins Return on Equity Return on Assets Pyxis OncologyN/A -57.49% -45.17% Lipocine N/A -26.68%-24.77% Do insiders and institutionals believe in PYXS or LPCN? 39.1% of Pyxis Oncology shares are owned by institutional investors. Comparatively, 9.1% of Lipocine shares are owned by institutional investors. 10.6% of Pyxis Oncology shares are owned by insiders. Comparatively, 6.4% of Lipocine shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. SummaryPyxis Oncology beats Lipocine on 9 of the 15 factors compared between the two stocks. Get Lipocine News Delivered to You Automatically Sign up to receive the latest news and ratings for LPCN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding LPCN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart LPCN vs. The Competition Export to ExcelMetricLipocineMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$17.76M$2.45B$5.61B$9.11BDividend YieldN/A1.79%5.24%4.02%P/E Ratio-3.219.4227.9620.25Price / Sales1.56729.02430.8999.65Price / CashN/A165.3637.4658.16Price / Book0.834.608.045.49Net Income$10K$31.26M$3.18B$250.27M7 Day PerformanceN/A4.80%3.67%4.80%1 Month Performance3.48%5.42%4.09%7.68%1 Year Performance-57.48%-4.36%29.58%16.36% Lipocine Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)LPCNLipocine2.7099 of 5 stars$3.27-1.5%$9.00+175.2%-57.4%$17.76M$11.20M-3.2110PYXSPyxis Oncology2.2902 of 5 stars$1.10flat$9.00+718.2%-60.9%$68.14M$16.15M-0.6960Positive NewsBMEABiomea Fusion3.3911 of 5 stars$1.80-0.6%$21.40+1,088.9%-59.7%$68.01MN/A-0.5150Positive NewsINCRInterCure0.6732 of 5 stars$1.47-1.3%N/A-34.9%$67.90M$66.28M0.00350Positive NewsHigh Trading VolumeABOSAcumen Pharmaceuticals2.9281 of 5 stars$1.16+3.6%$6.33+446.0%-46.6%$67.84MN/A-0.6020News CoverageIMUXImmunic2.5454 of 5 stars$0.70-0.4%$11.60+1,563.1%-38.1%$67.07MN/A-0.5770IKNAIkena Oncology2.7738 of 5 stars$1.34-1.5%$3.00+123.9%-16.4%$65.63M$9.16M-1.5670News CoveragePositive NewsMNOVMediciNova1.7663 of 5 stars$1.31-1.5%$7.00+434.4%-8.6%$65.23M$1M-5.7010Gap DownIZTCInvizyne TechnologiesN/A$10.39+6.8%N/AN/A$64.96MN/A0.0029Gap DownADAPAdaptimmune Therapeutics2.1876 of 5 stars$0.24-2.2%$1.35+463.9%-78.3%$64.94M$178.03M-0.89490Positive NewsGap DownIGMSIGM Biosciences4.6162 of 5 stars$1.12+3.7%$5.50+391.1%-85.4%$64.56M$2.68M-0.34190Positive News Related Companies and Tools Related Companies PYXS Alternatives BMEA Alternatives INCR Alternatives ABOS Alternatives IMUX Alternatives IKNA Alternatives MNOV Alternatives IZTC Alternatives ADAP Alternatives IGMS Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:LPCN) was last updated on 7/12/2025 by MarketBeat.com Staff From Our Partners3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lipocine Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lipocine With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free LPCN Stock Alerts